

INDEX

Note: Italicized letters *f*, and *t* following page numbers indicate figures and tables, respectively.

- 3 Rs (replacement, reduction, refinement)
 - see* humane animal use in research
- 15 day report, 639
- 505(b) (New Drug Application)
 - (1) (traditional), 41
 - (2) (small molecules), 41, 269, 711
- 510(k) (premarket notification for a change in a device), 50, 714

- absorption, 81–111, 384–389, 589
 - inhalation, 385, 464
 - lymphatic channels, 88
 - oral, 86, 384
 - parenteral, 84
 - pulmonary system, 386
 - skin, 84, 387, 474
 - weak acids and bases, 89
- absorption, distribution, metabolism, excretion (ADME), 108*t*, 110, 166*t*, 213, 312*f*, 382, 395, 397, 406, 437, 509, 526*t*, 539, 543*f*, 556*t*
- active cutaneous anaphylaxis assay (ACA), 251, 259
- active systemic anaphylaxis assay (ASA), 259
- active transport, 83, 88, 385, 397
- “activity criterion,” 83, 88, 385, 397
- adaptive immunity, 228
- adaptive repair pathway, 172
- adduct formation, 173, 324

- adulteration, 107
- adverse drug event (ADE), 641–647
- adverse drug reaction (ADR), 593, 622–626, 629, 641–647
- adverse effects, 115, 226, 295–304, 526*t*
- adverse event (AE), 242, 452, 508, 586, 592, 643*f*, 646, 740
- age adjustment, 671
- agonal signs, 140
- alanine aminotransferase (ALT), 124*t*, 277*t*, 282, 355*t*, 612*t*, 787*t*
- albumin-to-globulin ratio (A/G), 248, 355
- alkaline phosphatase (ALP), 121*t*, 122*t*, 124*t*, 355*t*, 473, 612*t*, 613
- allergenicity, 235, 259–261, 440, 555*f*
- alternation, 295, 422
- Ames, Bruce, 181
 - mutagenicity data, 214, 220*t*
 - salmonella/plate incorporation method, 177, 181–185
 - test, 9*f*, 183
- analog plot, 75–76
- analysis
 - covariance (*see* Analysis of Covariance (ANCOVA))
 - screening data, 73, 154, 545
 - tumor incidence, 330–342, 654, 667, 673
 - variance (*see* Analysis Of Variance (ANOVA))
- Analysis Of Covariance (ANCOVA), 285–287, 677–705
- Analysis Of Variance (ANOVA), 284–287, 653–705
- anaphylactic reactions (anaphylaxis), 85, 227, 235, 236*t*, 245*t*, 254, 259, 442–446
- aneuploidy, 176–177, 196, 326
- animal husbandry, 193, 330, 374, 375
- animal models, 263, 292*t*, 382, 385, 409*t*, 455, 515, 732–738 *see also names of specific animals*
- Animal Welfare Act (AWA), 161, 270, 519
- antibiotics, 15, 23, 233–238, 292*t*, 715
- antibody-mediated hypersensitivity *see* antibody-mediated; hypersensitivity, type II (cytotoxic)
- antigenicity, 226, 242, 415*t*, 434*t*, 435*t*, 437*t*, 438*t*, 451–455, 542
- antimetabolites, 232, 233*t*, 259, 292*t*
- Anxiety Status Inventory (ASI), 616
- Area Under the Curve (AUC), 399*t*, 405*t*, 493, 587*t*
- Armstrong method, 258
- Arthus reaction *see* hypersensitivity
- aspartate aminotransferase (AST), 124*t*, 277*t*, 282, 355*t*, 612*t*, 787*t*, 788*t*, 814*t*

- assays *see also names of specific assays*
 chromosomal and genomic mutations, 178*t*
 cytotoxicity, 187–190
 dominant lethal, 178*t*
 gene mutations, 49, 178*t*, 542, 574*t*, 842*t*
 host resistance, 245*t*
in vitro cytogenetic, 49, 178*t*, 193–196, 556*t*
 isolated tissue pharmacological, 420*t*
 local lymph node assay (LLNA), 255–258, 530*t*, 567
 neurochemical, 421
 Asthma, 235, 444*t*, 465, 651
 inhaler, 2*t*
 autoimmunity, 225–248, 264
 Avogadro's law, 470
- bacterial mutation tests, 180
 Bartlett's Test of Homogeneity of Variance, 666*f*, 673–675, 686, 705
 base substitution, 173, 174, 182, 185
 Baycol, 630*t*, 635*t*, 649, 650
 Bayesian inference *see* Bayes' Theorem
 Bayes' Theorem, 702–705
 B-Cell lymphoproliferation response, 249
 B cell /T cell ratio, 227–250
 B6C3F1 mice, 253, 328–334
 beagle, 35, 147, 270–273
 Beck Depression Inventory, 613*t*, 616
 behavioral
 rating scales, 613*t*, 619
 tests, 303, 618, 735
 Bender-Gestalt test, 613*t*, 620
 benign neoplasia, 334–335
 Bernard, Claude, 4
 b-estradiol *see* estradiol
 bias, 285, 298, 333, 341, 622, 655
 bidirectional drug effects, 413
 bile, 92, 124*t*, 392–395, 398–400, 612*t*
 bilirubin, 121*t*, 122*t*, 124*t*, 272, 277*t*, 355*t*, 371, 588*t*, 612*t*
 bioavailability and thresholds, 90–91
 biochemical assays, 421
 bioengineered products, 455
 classification, 435*t*
 biological significance *see* significance
 Biologic License Application (BLA), 7*t*, 19, 39*t*, 594*f*
 biologics, 14*t*, 24, 305*f*, 408, 437*t*, 438*t*, 458, 517, 594*f*
 Biologics Control Act *see* Virus Act of 1902
 biomarkers in heart failure, 615*t*
 biotechnology products, 30, 43*t*, 253, 264, 433–459, safety evaluation program 454
 bioprocess technology, 446
 biosimilars, 458*t*
 gene therapy products, 446
 immunogenicity/allergenicity, 440
 monoclonal antibody technology, 441
 preclinical safety assessment, 437
 recombinant DNA technology, 439
 regulation, 436
 vaccines, 449
 biotransformation, 47, 98, 218, 383*t*, 389–408
 BLA *see* Biologic License Application (BLA)
 b-lactam antibiotics, 233–240
 blockbuster biotechnology approvals, 434*t*
 blocking, 661
 blood
 collection, 270, 275, 397
 compatibility, 82, 104, 367, 486*t*, 517*t*
 red cells, 124, 239, 249, 568, 612*t*
 Urea Nitrogen (*see* Blood Urea Nitrogen (BUN))
 Blood Urea Nitrogen (BUN), 121*t*, 122*t*, 520, 612*t*
 body and organ weights, 705
 body water, by species, 389*t*
 body weight, 37, 105, 116–126, 144, 145*t*, 271–276, 299, 309*f*, 705
 bolus, 164*t*, 272
 bolus vs. infusion, 85, 272, 367
 botanical drug products, 38
 Bovine Corneal Opacity (BCOP), 364, 564, 574*t*
 bovine serum albumin (BSA), 253
 Buehler Assay (BA) *see* Buehler test
 Buehler test (Buehler assay (BA)), 244*f*, 254–259
 Bureau of Biologics (now CBER), 30, 436*t*
- Canadian Centre for Occupational Health and Safety (CCINFO), 64
 capsular polysaccharide vaccine, 449
 captopril, 235*t*, 239, 240
 carcinogenesis, 174, 322, 707
 mechanisms and theories of chemical, 327
 carcinogenicity studies, 321–345
 carcinogens
 epigenetic, 325
 genotoxic, 174, 322
 human, 327
 mechanisms and classes, 322
 cardiotoxicity, 216, 279, 467
 cardiovascular system
 measurements, 282
 safety pharmacology evaluations, 414*t*
 toxicity, 279
 Carroll Rating Scale for Depression, 617
 case I, II, III, IV *see* significance
 Case Report Forms (CRF's), 597
 categorical and ranked data, 679
- causality
 adverse drug reactions, 622
 assessment, 622, 647
 CDER flowchart *see* specific immunotoxicity testing
 cell-mediated immunity, 228*t*, 250
 cellular
 components of immune system, 227–260
 therapies, 33–35
 tissue implants, 711
 censoring, 144, 653, 661, 662, 684
 Center for Biologics Evaluation and Research (CBER), FDA, 19–55, 436, 446, 714–715, 738 *see also* Bureau of Biologics
 Center for Devices and Radiological Health (CDRH), 50–54
 Centers for Disease Control and Prevention (CDC), 640
 central nervous system, 415, 419
 central tendency plots, 74
 chelation, 83*t*, 397*t*
 Chernoff's faces, 697
 Children's Behavior Inventory (CBI), 613*t*, 619
 Children's Diagnostic Scale (CDS), 613*t*, 619
 Chinese Hamster Ovary (CHO), 185, 194
 Chinese hamster V79/HGPRT (hypoxanthine-guanine phosphoribosyltransferase) assay, 178, 185, 187, 194
 Chi Square, 666*f*
 chromosomal aberrations (CAs), 170
 chromosome set damage, 170, 177
 chronic studies, 111, 144, 159
 chronic toxicity, 29*t*, 36, 44, 75, 108*t*, 110*t*, 400, 434*y*, 541*t*, 706
 Cisapride (Propulsid), 630*t*
 Class B sources, 280
 classifying clinical studies according to objective, 599*t*
 clearance, 383*t*, 402–410
 hepatic, 383*t*
 inhaled aerosols, 464
 renal, 284*t*
 total, 284*t*
 clinical
 chemistry, 117–126, 242*t*, 248, 355, 612*t*, 613, 706
 observations, 116, 117*t*, 139–146, 272, 282
 pathology, 117, 121*t*, 243*t*, 299, 355, 520
 signs, 96, 117, 118*t*, 139*t*, 140, 155*t*
 Clinical Trial Application (CTA), 10
 Clinical Trial Certificate Exemption (CTX), 22
 clinical trial safety indicators, 609
 Clinical Trials Certificate (CTC), 22

- cloned human potassium channels, 419
 clumping techniques, 699
 cluster analysis, 699
 Cochran t-test, 666*f*, 685
 combination products, 49, 711
 comet assay, 178, 190–192, 556*t*, 724*t*
 Committee for Proprietary Medicinal Products (CPMP), 241*t*, 328, 414*t*, 418, 637
 common data transformations, 678*t*
 comparative metabolic “fingerprinting,” 382
 compassionate use, 35
 complete acute toxicity testing, 142
 computed tomography (CT), 399, 738
 concurrent control, 68, 115, 147, 153, 342, 659
 congressional committees responsible for FDA oversight, 40*t*
 CONSAM data modelling software, 403
 contaminated diphtheria toxins, 13, 436*t*
 contrast agents, 484, 509
 control charts, 73
 convective absorption, 88
 correlation coefficient, 693
 Council for International Organizations of Medical Sciences (CIOMS), 593, 639, 646
 Cox-Stuart test, 670
 Cox-Tarone binary regression, 341
 creatinine phosphokinase (CPK), 121*t*, 122*t*, 371, 612, 613, 706
 Crestor, 2*t*, 650
 curve-stripping, 403
 cyclooxygenase 2 (COX-2), 353, 540*t*, 635*t*
 cyclosporine, 232
 cytochrome P-450 (CYPs) isoenzymes, 9, 276, 314*t*, 382, 389–394
 cytogenetics, 176–193
 cytokines, 248, 736, 740
 cytokine storm, 225, 442
 cytotoxic
 hypersensitivity (*see* antibody-mediated); hypersensitivity, type II (cytotoxic)
 T_k (T killer) cells, 228, 230*t*, 251
 cytotoxicity
 assay, 187–190, 196
 confounding factor, 191
 cytotoxic T Lymphocyte-mediated assay (CTL), 250
- Data and Safety Monitoring Boards (DSMBs), 596
 data recording, 196, 664
 dechallenge, 624, 642
 decision tree, 151, 212, 311*f*, 665*f*, 675*f*, 706
 hypothesis testing procedures, 666*f*
 modeling procedures, 666*f*
 reduction dimensionality procedures, 667*f*
- Declaration of Helsinki, 591, 598
 degradation products, 177, 724
 delayed contact hypersensitivity, 216, 226, 263, 567
 delayed liver toxicity (DLT), 216, 570, 586
 Delayed-Type Hypersensitivity (DTH) *see* hypersensitivity, type IV (Delayed-Type Hypersensitivity (DTH))
 deposition of inhaled aerosols, 463
 dermal
 formulations, 100
 irritation test, 566*t*
 route, 82–83, 461, 474
 toxicity, 108–110, 278
 determination of pregnancy, 301
 developmental and reproductive toxicity (DART), 28, 44, 291–316, 506
 Developmental And Reproductive Toxicology (DART), 28, 842–860
 diagnostic radiopharmaceuticals, 484, 487, 516
 diethylene glycol, 11, 16, 96, 604
 diethyl ether (“sweet oil of vitriol”), 4, 5, 469
 diethylstilbestrol (DES), 233*t*, 234, 326
 Dimethylformamide (DMF), 102, 104
 dimethylsulfoxide (DMSO), 102, 104, 182, 758*t*
 distribution-free multiple comparisons, 682
 DNA adducts, 174, 190*t*, 322–323
 DNA/oligonucleotide hybridization, 450
 dog, 37*t* 95*t*, 147–148, 161*t*, 164*t*, 165*t*, 260, 270–273, 280*t*
 beagle, 147, 273*t*
 hemodynamics, ECG and respiration studies, 417
 6-lead ECG measurements, 417
 telemetry studies, 417
 dominant lethal assay, 178*t*
 dose-range finders (DRFs), 154, 166, 438*t*, 475*t*, 492*t*, 548
 dose ranging and selection, 184
 dose-response relationship, 68, 76*f*, 139*t*, 161, 261, 301, 330, 353*t*, 415, 468, 597, 660, 667*t*, 691
 dose selection, 131, 330
 dosing calculations, 105
 D-penicillamine, 235*t*, 237–240
 Draize test
 eye irritation, 362, 531, 564
 skin irritation, 360, 374
 drug
 allergies, 226
 botanical products, 41
 distribution, 505, 591
 formulations, 604
 immunostimulation, 235–243
 metabolites, studies of, 601
 new, 41, 60*f*, 242, 458, 461, 538, 543*f*
 safety withdrawals, 637–638
 singularity, 624
 supplies, 596
 withdrawn, 630*t*
 Drug Master File (DMF), 23, 107–109
 drug metabolism and pharmacokinetics (DMPK), interspecies differences, 394
 Dry Powder Inhalers (DPIs), 461, 465, 472, 728
 DTH *see* hypersensitivity, type IV (Delayed-Type Hypersensitivity (DTH))
 Duncan’s Multiple-Range Test, 666*f*, 687
 Dunnett’s t Test, 666*f*, 688
- earthworms, 557, 562–563
 EC seventh amendment, 525*t*
 Ehrlich, Paul, 4, 79
 electrocardiograms (ECGs), 271*t*, 272, 274, 282, 315*t*, 417
 electroencephalogram (EEG), 421, 610
 elixir of sulfanilamide, 16, 19, 352, 604
 embryo-fetal development, 44, 47*t*, 293, 295–308, 498
 endoplasmic reticulum, 179, 351, 466
 environmental impact, 23, 563
 enzyme induction, 351, 383*t*, 605
 Enzyme-Linked Immunosorbent Assay (ELISA), 248, 253, 407, 454, 741
 epigenetic carcinogenesis, 325–327
Escherichia coli (*E. coli*), 172–182, 450
 HS-4, 440
 polypeptides, 453
 proteins, 453
 tester strains, 183
 estradiol, 233–234
 estrogens, 234, 326, 344*t*
 ethical tenets, IRBs, 602
 European Economic Community (EEC), 526, 542, 563
 European Medicines Agency (EMA), 124, 240, 312, 382, 413, 437, 446, 728, 731, 739
 European Union (EU), 41, 47, 241, 637, 646
 excipients, 79, 96, 97*t*, 106–110, 367, 725
 drug formulations, 604
 regulation, 168–170
 excision repair, 171, 182, 190, 321
 excretion, 175*f*, 191, 383*t*, 394, 398, 509, 741*t*
 expired air, 395, 398
 Exploratory Data Analysis (EDA), 67, 284, 544, 673, 678
 expression cloning, 451
 extractables, 711, 721, 727–728
 extrathoracic, 461, 463

- faces *see* Chernoff's faces
- facilitated diffusion, 88
- "false negative" *see* biological significance; statistical
- "false positive" *see* biological significance; statistical
- federal drug law, important dates, 14*t*
- Federal Virus-Serum-Toxin Act (TOPN), 436*t*
- feed consumption, 139*t*, 143*f*, 144, 146*f*, 153*f*, 271*t*, 272, 274, 282
- female reproductive studies, 49
- ferret, 273–275
- fertility, male and female, 294 *see also* reproductive studies; sterility
- fetal
- examinations, 301–305
 - risk summary, 310
- fiducial limit, 143*t*, 655*t*, 656
- First-In-Man (FIM), 8, 10, 124, 442, 599
- Fischer 344 (F344), 253, 328–338, 343*t*
- Fisher's exact test, 666*f*, 679
- fixed-dose procedure, 135, 136*t*
- flip-flop pharmacokinetics, 403
- fluidized-bed dust generator, 472
- Food and Drug Administration
- Modernization Act (FDAMA), 18, 19, 23, 37
- Food Drug and Cosmetic (FD&C) Act, 106, 436*t*, 602
- Kefauver-Harris amendment, 17, 636
- Form 3500/3500A *See* U.S. Food and Drug Administration (FDA)
- formulation, 79–111, 371, 473, 604
- dermal, 100
 - development, 97
 - excipients, 604
 - interactions, 102
 - mucosal damage, 473
 - oral, 103
 - parenteral, 104
 - test materials, 96
- forward mutation tests, 180, 185
- Fourier (time) analysis, 667*f*, 695, 699
- frameshift mutations, 173, 181, 323
- functional observational battery (FOB), 74*f*, 117*t*, 118*t*, 146, 155*t*, 270, 419
- functional reserve capacity, 264
- Gantt chart, 542–545
- gastric emptying rate, 386*t*, 400, 415, 427
- gastric pH changes, 89, 427
- Gelsinger, Jesse, 446
- gene
- regulation, 171
 - therapies, 34–35, 446
 - therapy products, 447
- general case oral drug, 9*f*
- general criteria affecting drug/device determination, 54
- Generally Recognized As Effective (GRAE), 52, 717
- Generally Regarded As Safe (GRAS), 52, 109, 483, 717
- genotoxic *vs.* nongenotoxic mechanisms of carcinogenesis, 174
- genotoxicity, 32, 169, 198, 215, 486*t*, 493*t*, 574*t*
- tests recommended by ICH, 516
- Geometric Standard Deviation (GSD), 463–472
- geriatric claims, 37
- germ theory, Louis Pasteur, 4
- Gilbert's syndrome, 418, 588*t*
- glucocorticosteroids, 232
- glutamate dehydrogenase (GDH), 124*t*
- Good Clinical Practices (GCP), 592
- Good Laboratory Practices (GLP), 161, 519
- Good Manufacturing Practices (GMP), 24, 31
- goodness-of-fit tests, 676
- granuloma formation, 238
- gravid uterine weights, 299–300
- guinea pig, 374
- Guinea Pig Maximization Test (GPMT), 244*f*, 244*t*, 254–256, 256*f*
- Haber's rule, 468
- Hamilton Anxiety (HAMA) scale, 613*t*
- HAMilton Depression (HAMD) scale, 613*t*
- Harber and Shalita Method, 258
- hazard assessment, 67, 531
- heavy metals, 60, 234
- hematocrit, 121*t*, 612*t*, 613, 706
- hematology, 1, 355*t*, 520
- hemodynamics, 315*t*, 414*t*, 417
- hemolytic potential, 378
- hepatocyte, 382, 391*t*, 572*t*
- hierarchical techniques, 699
- histograms, 75, 674
- histopathological lesion incidences, 706
- histopathology, 125, 351, 520
- tissues, 352*t*
- historical controls, 154, 165, 304, 342, 673, data. 72*f*
- homologue, 409
- homology, 439, 453
- host resistance assays, 245*f*
- human carcinogens *see* carcinogens, human
- humane animal use in research, 544
- Human Equivalent Doses (HED), 446
- human Ether- α -go-go-Related Genes (hERG), 70, 216, 419
- humanizing mice, 457
- human peripheral blood lymphocytes, 194, 567
- Human Repeat Insult Path Test (HRIPT), 258
- humoral
- immune response, 246
 - immunity, 228*t*, 229*t*, 231
- Hydra* system, 316
- hydrolysis, 171, 324, 390*t*
- hydroxybutyric dehydrogenase (HBDH), 122*t*, 706
- hyperpharmacology, 159, 225, 433, 550
- hyperplasia/hyperplastic, 246*t*, 326, 667
- hypersensitivity
- type I (immediate; reaginic), 235, 253
 - type II (cytotoxic; antibody-mediated), 234, 235, 237, 240, 242*t*, 253, 259
 - type III (Arthus reaction), 236*t*, 237, 242*t*, 259
 - type IV (Delayed-Type Hypersensitivity (DTH)), 235*t*, 237, 238, 250, 254, 258
- hypoxanthine-guanine phosphoribosyltransferase (HGPRT), 178
- identification threshold, 215, 722–725
- imaging agents, 483
- immune system, 125, 225, 245
- immunoassay methods, 253, 397, 407
- immunogenicity, 259
- biotech drugs, 261
- immunomodulatory drugs, 263, 417*t*, 586
- immunopathological assessments, 227, 246
- immunostimulation, 235–243
- immunosuppression, 231, 242
- immunotoxicology, 126*t*, 225, 260
- implant counts, 301
- impurities, 215, 721
- inactivated vaccines, 449
- inactive metabolites, 561*t*
- inducing agents, 179
- informed consent, 603
- inhalation, 29*t*, 82, 108, 110, 385, 461
- inhalation exposure techniques, 470
- in-life phase, 549
- innate immunity, 227
- insertional mutagenesis, 448
- Institutional Review Board (IRB), 602
- insulin pump, 711
- interactions between skin, vehicle, and test chemical, 102
- Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), 135, 575
- intercenter consultation, 51
- interferons (IFNs), 230*t*, 264, 408, 433
- interleukins, 264, 433
- International Classification of Diseases 9th Revision, Clinical Modification (ICD-9 CM), 645
- 10th Revision (ICD-10), 645

- International Conference on Harmonisation (ICH) *see also* S1.2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- International Federation of Pharmaceutical Manufacturers Association (IFPMA), 44, 640
- International Pharmaceutical Excipients Council (IPEC), 79, 109
- interspecies differences, 166, 394, 473, 532
drug metabolism and pharmacokinetics (DMPK), 394
- intramuscular route, 86, 272, 281*t*, 367
- intraperitoneal route (IP), 81, 86, 447, 515
- intravenous route (IV), 84
- Investigational Drug Exemption (IDE), 33, 51–54, 716
- Investigational New Drug (IND), 23*t*, 242
enabling, 17, 35–36 (*See also* First-In-Man (FIM))
- in vitro* cytogenetic assays, 193
- Irwin screen, 419
- isolated tissue pharmacological assays, 420*t*
- Japan, 1, 47, 424*t*, 542, 646
- Johns Hopkins, 591
- Kaplan–Meier, 341, 684, 700
- Karnofsky’s Law, 308
- Kefauver–Harris amendment *see* Food Drug and Cosmetic (FD&C) Act
- Kelsey, Francis, 17
- Kendall’s coefficient of rank correlation, 666*f*, 694
- kidneys, 122*t*, 125*t*, 155, 237, 254, 352*t*
slices, 302
- “kill the losers as early as possible,” 8
- “known to be human carcinogens” *see* carcinogens, human
- Kruskal–Wallis nonparametric tests, 183
- lactate dehydrogenase (LHD), 124*t*
- latent period, 174, 278, 520, 623
- leachables, 721–728
- Lethal Dose 50% (LD₅₀), 47, 88, 96, 130–156, 214–219, 560
- lethality, 116*t*, 214, 560
- lethality testing, 130
- levels of models, safety assessment, 557*t*, 794
- life table analysis, 667*f*
- life tables, 339, 683, 700
- limit doses for toxicological studies, 110*t*
- limit tests, 134
- Limulus* Amebocyte Lysate (LAL) test, 377, 573
- linear regression, 183, 653, 666*f*, 691
- lithium, 235, 240
- litter size, effect of, 296, 305–306, 398
- liver toxicity, 124*t*, 153, 467, 570
- local effects, 81, 463
- Local Lymph Node Assay (LLNA) *see* assay, LLNA (local lymph node assay)
- longitudinal analysis, 284
- Lotronex, 540*t*, 631*t*
- lupus, 229*t*, 232, 240, 422*t*, 423*t*
- macrophage function, 231, 251
- “magic bullets,” 5, 6, 80*f*
- Magnusson and Kligman, 255
- Major Histocompatibility Complex (MHC), 228, 231, 237
- malformation, 175, 295, 304–309
- Mann–Whitney U test, 284, 682
- Marketing Authorization Application (MAA), 23
- Mass Median Aerodynamic Diameter (MMAD), 463
- Material Safety Data Sheets (MSDS), 63
- maximum likelihood, 131, 288, 342, 676
- Maximum Nonlethal Dosage (MNL), 137
- Maximum Recommended Human Dose (MRHD), 331
- Maximum Tolerated Dose (MTD), 331, 475*t*
- measurement of drug activity, early, 600
- mechanisms and theories of chemical carcinogenesis, 327
- median, 635*t*, 638*t*
- Medical Dictionary for Regulatory Activities (MedDRA), 645
- MEDLINE, 64
- MedWatch, 452, 636, 639–642
- Merck, 3, 5
- Merck Index, 62
- meta-analysis, 662, 701
- metabolic activation, 110*t*, 178, 198, 323, 392
- metabolism cages, 272, 275, 398, 401
- metabolites, studies, 416
- metal catalysts and metal reagents, class exposure and concentration limits, 729*t*
- metered-dose inhaler (MDI), 472, 721
- micronuclei, 170*t*, 197, 574*f*
- micronucleus test, 108*t*, 110*t*, 197, 574*t*, 724*t*
- minimal acute toxicity test, 139
- Minimal Lethal Dosage (MLD), 134, 137
- Minimum Active Biological Effective Level (MABEL), 446
- minipig, 275, 417
- missing data, 672
- missing values, 288
- mitochondrion, 115, 351, 389
- mitochondrial mixed functional oxidase (MMFO), 277
- Mixed-Lymphocyte Response (MLR) assay, 250
- modeling, 210, 404, 690
- monoclonal antibodies (mAbs), 228*t*, 408*t*, 442
- Mouse Lymphoma Assay (MLA), L5178YTK[±], 178, 187, 192
- mouse specific locus test, 193
- mucociliary transport system, 385, 466
- MultiDimensional Scaling (MDS), 695, 697
- multiple comparisons, 183, 285, 656, 682, 688
- multivariate data, 75, 545, 696–699
- multivariate techniques, 285
- muromonab-CD3; Orthoclone OKT3 (OKT3), 442, 444*t*
- muscle irritancy, 371, 566
- mutations, 172, 173
- myelosuppression, 232–234
- nasal administration, 91*f*, 94, 282
- Natalizumab *see* Tysabri
- National Library of Medicine (NLM), 62
- natural killer (NK) cells, 230*t*, 231, 233*t*, 235*t*, 251, 313*t*
- natural products, 5–7, 24*t*, 715*t*
- negative accuracy, 68, 546
- neoplasia, events leading to, 175*f*
- neurochemical assays, 421
- neuromuscular screen, 139*t*, 146, 147*t*, 546
- neurotoxicology, 125, 126*t*, 421
- New Chemical Entities (NCE), 129, 192, 406, 525, 593
- New Drug Application (NDA), 14*t*, 17, 22–25, 29*t*, 36, 41, 242, 486*t*, 517*t*
- new drug, definition, 22
- nitrogen mustards, 234, 323
- N-nitrosodimethylamine (NDMA), 672
- NonHuman Primate (NHP), 147, 269, 279
- NONLIN, 403
- nonlinear regression, 222, 666*f*, 692
- nonmetric scaling, 697
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), 417*t*, 635*t*, 638*t*
- No-Observable-Effect Level (NOEL) estimation, 310, 669, 726–727
- normalize the data, 677
- No-Statistical-Significance-Of-Trend (NOSTASOT) dose, 671
- Nuremberg Code, 591
- occupational exposure limits (OELS), 531
- Occupational Safety and Health Administration (OSHA), 63, 215, 525–532
- occupational toxicology, 523
- Occupational Toxicology Roundtable, 531
- ocular irritation testing, 219, 362, 564

- off-target effects, 433
- oncology
- cytotoxic, 492, 606
 - drugs, 8, 489
 - imaging, 510
 - protein-targeted molecules, 492*t*
- one-tailed comparisons, 338
- optical isomers, 36
- oral
- absorption (k_a), 400
 - contraceptives, 35, 422*t*
 - elimination (E), 403
 - formulations, 103
 - route, 86
- Organisation for Economic Co-operation and Development (OECD), 30*t*, 178*t*, 560*t*, 574*t*
- organ weights, 117*t*, 124, 155*t*, 166*t*, 241*t*, 246*t*, 354, 389, 520
- Orphan Drugs, 14*t*, 38
- osmoreceptor, 386*t*
- oxidation, 390*t*
- Paracelsus, 467
- parenteral
- formulations, 104, 166, 371
 - irritation, 367–369
 - route, 367
- partition coefficients, 83, 87, 210, 385, 397
- passive absorption, 87, 392
- Passive Cutaneous Anaphylaxis (PCA) assay, 251, 415
- Pasteur, Louis, 4
- “patent medicines,” 5
- patients with renal and hepatic dysfunction, 601
- pediatric claims, 19
- Pediatric Use Labeling Rule, 37
- periocular route, 94
- permissible dosing volumes for nonhuman primates, 281*t*
- Permitted Daily Exposure (PDE), 726–729
- Peto Analysis, 341
- Pharmaceutical Research and Manufacturers of America (PhRMA), 37, 526, 538, 583
- pharmacodynamics, 304, 406, 437*t*, 464, 586, 589, 599*t*, 600, 712, 754
- pharmacogenetics, 556, 589
- pharmacokinetics, 47, 164, 381, 395, 464, 589
- pharmacovigilance (PV), 414, 597, 637
- phase 0 (safety) studies, 129, 456
- phase I (metabolism) studies, 170*t*, 390*t*
- phase II (drug efficacy) studies, 70*t*
- phase III (clinical, therapeutic confirmatory) studies, 328
- phase III/IV (therapeutic use) studies, 599*t*
- phase IV (postmarketing) studies, 586
- phase Ib/I (therapeutic exploratory) studies, 314*t*
- phocomelia, 636
- photosensitization, 238, 258, 372, 555*f*, 566–568
- phototoxicity, 108*t*, 238, 278, 371–376
- Physiologically Based Pharmacokinetic (PBPK) modelling, 404–405, 531*t*
- pie charts, 696–697
- pig, 275, 417
- pilot toxicity studies, 154
- pinocytosis, 88, 408
- placebo control, 606
- Plaque-Forming Cell (PFC) assay, 242, 249, 253
- plasma protein binding, 83*t*, 382, 388
- plasmids, 172, 173
- platelets, 123*t*, 124, 234, 244*t*
- platinum salts, 729
- p53^{+/−}-mouse model, 336
- polypharmacy, 497, 625
- pooling, 668, 801
- positive accuracy, 68, 546
- post hoc* tests, 679, 687
- postnatal development, 37, 47, 295–315
- potential new drugs in U.S. clinical trials, 7
- Precision, Accuracy, Sensitivity, Selectivity (PASS) validation, 154
- preclinical male fertility studies, 48
- pregnancy *see* developmental and reproductive toxicity (DART)
- preincubation tests, 183
- pre-IND
- meeting, 9*f*, 38
 - nonclinical safety, 493
- preliminary cytotoxicity testing, 186
- preliminary studies, 297
- premarket approval applications (PMA), 594*f*
- prenatal development, 47, 295–315
- Prescription Drug User Fee Act (PDUFA), 18, 434*t*, 648
- Primary Dermal Irritation (PDI) test, 360
- primary mode of action (PMOA), 711–719
- probit/log transforms, 691
- probit method, 132, 149
- product class review responsibilities, 24*t*, 715*t*
- product withdrawals, safety reasons, 649
- Program Evaluation and Review Technique (PERT), 542, 543*f*
- project management, 542
- Prospulsid *see* Cisapride
- protein binding, 381, 384*t*, 388
- pulmonary
- sensitization, 108*t*, 466
 - system, 313*t*, 386
- Pure Food and Drugs Act of 1906, 13, 436*t*
- Purkinje fibers, 418
- p value, 338–342, 655–656
- “pyramiding” studies, 133–138, 147
- pyrogenicity, 376, 452, 566, 573
- Q3A, ICH (impurities in new drug substances), 721–725
- Q3B(R2), ICH (impurities in new drug products), 725
- Q3C, ICH (impurities, guideline for residual solvents), 24, 725, 732
- QT/QTc, 42*t*
- qualification threshold, 215, 722–725
- Quantitative Structure-Activity Relationship (QSAR) models, 69, 209–222, 321, 531, 546, 574*t*, 722
- rabbit, 28, 47*t*, 110*t*
- acute intramuscular irritation, 369
 - phototoxicity test, 373
 - vaginal irritation study, 365
- Radioactive Drug Research Committee (RDRC), 483
- radiochemical methods, 396
- Radio-Immune Assays (RIA), 254, 407
- Radithor, 15
- randomization, 116, 163, 365, 604, 661, 677
- range-finding study, 130–152, 297, 548, 708
- reaginics *see* hypersensitivity, type I (immediate; reaginic)
- receptors slowing gastric emptying, 386*t*
- rechallenge, 609, 624, 642
- Recombinant DNA Advisory Committee (RAC), 446, 738
- recombinant DNA technology, 7, 253, 433, 439
- rectal
- administration, 91*f*, 94, 386*f*
 - routes, 81, 384
- red blood cells (RBCs), 123*t*, 198, 239, 355*t*, 568, 612*t*
- reduction of dimensionality, 573, 655, 658, 694–699
- regulatory pyramid, 649
- relevance to humans, 342
- renal
- cells, 355, 490*t*
 - function, 312*t*, 413, 428, 601, 613
- repeat-dose studies, 30*t*, 568, 612*t*
- Research and Review Techniques (RRT), 575, 576, 578, 694–699

- reproducibility, 68, 329, 384, 546, 657.
- reproductive
effects, 116*t*, 176
studies, female, 49
- Request For Designation (RFD), 711
- residual
metals, 728
solvents, 487, 516, 725
- residuals, 678, 693
- respiratory system, 120*t*, 414, 422–425, 464, 571*t*
- Resusci-Dog, 554
- Reye's syndrome, 353, 496*t*
- Rezulin (troglitazone), 635*t*, 648
- rheumatoid arthritis (RA), 229*t*, 232–240, 514
- ribosomal DNA (rDNA), 5, 433, 439–455
- rising dose tolerance, 152
- Risk Evaluation and Mitigation Strategies (REMS), FDA, 648–651 *see also* tier 1, 2, 3, 4, 5
- “rolling” acute test, 547*f*
- routes of administration, 81, 91–93, 139*t*, 272, 282, 332, 483, 515, 524, 586, 601, 726
- rules for form design and preparation, 664*t*
- Safe Medical Devices Act (SMDA) of 1990, 713
- safety studies, 163, 253, 279, 425, 712, 722, 732
- sample size, 31, 68, 284, 332, 654*t*, 662
- sampling, 397, 659
- sampling interval, 399, 661
- Sandoz Clinical Assessment-Geriatric (SCAG) scale, 618
- scattergram, 673
- Scheffe's Multiple Comparisons, 688
- screens, 67, 150, 544, 614
- secondary organ system, 415, 427
- selection of dosages, 437
- semiquartile distance, 658
- sensitivity, 68, 73
- sequential sampling, 401
- Serum Glutamic Oxaloacetic Transaminase, a.k.a. AST (SGOT), 121*t*, 122*t*, 612*t*, 613
- setting doses, 163
- Severely Toxic Dose (STD10), 36, 492*t*
- S1, ICH (carcinogenicity studies), 44, 45*t*, 328, 345
- S2, ICH (genotoxicity studies), 45*t*, 199, 475*t*
- S3, ICH (toxicokinetics and pharmacokinetics), 45*t*
- S4, ICH (toxicity testing), 45*t*
- S5, ICH (reproductive toxicology), 44, 45*t*, 293*t*
- S6, ICH (biotechnological products), 24, 32, 45*t*, 437, 456
- S7, ICH (pharmacology studies), 45*t*, 49, 413, 414*t*, 418, 419, 486*t*, 517*t*
- S8, ICH (immunotoxicology studies), 45*t*, 126, 225, 240, 241*t*, 242, 245, 261, 345
- S9, ICH (nonclinical evaluation for anticancer pharmaceuticals), 46*t*, 169
- S10, ICH (photosafety evaluation), 46*t*
- S11, ICH (nonclinical safety testing), 46*t*
- significance
biological, 160, 191, 249, 260, 654, 705
case I, II, III, IV, 654
“false negative” (case III), 654
“false positive” (case II), 654
statistical, 154, 160, 196, 211, 341, 544, 654
- SIMUSOLV, 403
- singularity of drug, 624
- Sister Chromatid Exchange (SCE) assay, 176, 197
- six-lead ECG measurement, dogs, 417
- skeletal fetal examination, 302
- sorbitol dehydrogenase (SDH), 122*t*
- special classes of studies, 586
- special patient groups, 601
- special populations, 37, 601
- species selection, 162, 260, 439*t*, 455, 519, 732
- species selection for protein therapeutic, 439*t*
- specific immunotoxicity testing, CDER flowchart, 244*t*
- specificity, 68*t*, 214, 220, 406, 546, 597, 644, 702
- specific toxicity screening, 153
- Sprague Dawley rats, 106*t*, 305, 328, 343*t*
- Standard Error of the Mean (SEM), 658
- “statin,” 6
- statistical
analysis, 304, 338, 655, 665–707
graphics, by function, 696
randomization, 163
significance (*see* significance)
- status of nonanimal methods that have regulatory standards, 574*t*
- sterility, 367
- strategies for development, 8
- stratification, 585, 661, 668
- Structure-Activity Relationship (SAR), 210, 562, 804
- Student's *t* Test, 666*f*, 685
- studies of drug metabolites, 601
- subchronic study, 117, 131, 144, 161, 660
- subcutaneous (SC) route, 81, 85, 163, 281*t*, 367
- subunit vaccines, 449
- sulfonamide, 7*t*, 235*t*, 237, 344*t*, 422*t*
- Summary Basis of Approval (SBA), 23
- supplemented acute studies, 146
- suppressor mutations, 173
- survival, 332
- synthetic chemistry, 5, 7*t*
- Systemic Lupus Erythematosus (SLE), 232, 235*t*, 239, 354, 422*t*, 423*t*
- targeted therapeutics, 433
- target organ toxicity biomarkers, 331, 355
- Tarone's trend test, 669, 694
- T-Cell-Dependent Antibody Response (TDAR), 253
- T-Cell Lymphoproliferation Response, 250
- test material, 96, 682
- Tg.AC (v-Ha-ras) Transgenic Mouse Model, 335
- TGN1412, 11, 225, 433, 442
- Tg.rasH2 Mouse Model, 336
- thalidomide, 629, 636
- The Jungle*, (Upton Sinclair), 1, 436
- therapeutic drug delivery by dermal route, 474
- therapeutic index, 137, 381, 437, 537, 590, 608, 638*t*
- therapeutic products withdrawn from marketplace due to safety reasons, 630*t*
- Threshold Limit Value (TLV), 473, 523
- thresholds for action on impurities in drug product, 722*t*
- tier 1: mandatory studies, FDA REMS, 649
- tier 2: labeling and assessment, FDA REMS, 649
- tier 3: enhanced communication, FDA REMS, 650
- tier 4: safe-use restriction, defined by provider, FDA REMS, 650
- tier 5: safe-use restriction, defined by patient, FDA REMS, 651
- time course of effect, 591
- timing of studies, 297
- tissues for histopathology *see* histopathology
- T lymphocytes, 231
- tolerance, 544
- top 20 selling pharmaceuticals (2013), 2
- top 25 drug companies by sales (2014), 3
- TOPN (Federal Virus-Serum-Toxin Act), now Viruses, Serums, Toxins, and Analygous Products (2015), 436
- torsades de pointes* (TdP), 418, 636
- toxicokinetics, 297, 381
- Toxic Release Inventory (TRI), 63
- Toxic Substances Control Act (TSCA), 215, 525, 560*t*
- transcription, 171
- transformations, 667*f*, 677
- transgenic mouse models, 261, 335
- translation, 171, 451
- trend analysis, 666*f*, 669, 694

- trend tests, 340, 669
Troglitazone *see* Rezulin
TSCA *see* Toxic Substances Control Act
Tumor Necrosis Factor (TNF), 230*t*, 423*t*, 455, 615*t*
type I error (false positives), 68, 154, 546, 654, 655*t*, 687–689
type I hypersensitivity *see* hypersensitivity, type I (immediate; reagenic)
type II error (false negatives), 68, 546, 654, 655*t*
type II hypersensitivity *see* antibody-mediated; hypersensitivity, type II (cytotoxic)
type III hypersensitivity *see* hypersensitivity; type III (Arthus reaction)
type I immunotoxicity test, 126*t*
type IV hypersensitivity *see* hypersensitivity, type IV (Delayed-Type Hypersensitivity (DTH))
types of hypersensitivity responses, 236*t*
types of screens, 71
Tysabri (Natalizumab), 444*t*, 540*t*
- unconjugated bilirubin (UBili), 124*t*
univariate
 parametric tests, 684
 repeated-measures, 284
- unscheduled DNA synthesis (UDS) assay, 178*t*, 190*t*, 574*t*, 724
up/down method, 131, 152
urinalysis, 117*t*, 121*t*, 355*t*, 428*t*, 614
urine, 612*t*, 614, 706
U.S. Code of Federal Regulations (CFR)
 biotechnology products, 436
 clinical trial subjects, 592, 593
 21 CFR (drugs and medical devices, testing, manufacture, sale), 21–24, 51
 excipients, 106–109, 107*t*
 FDA submissions, 716
 imaging agents, 483
 IRBs, 602–603
 radiopharmaceuticals, 517
 regulatory requirements, 639–640
U.S. Food and Drug Administration (FDA), 13–19
 Form 3500/3500A, 593, 640, 643*f*
 Redbook II, 249, 293*t*, 331, 333, 382
 Risk Evaluation and Mitigation Strategies (REMS), 648
U.S. Pharmacopeia (USP), 25, 60, 106, 728
- Vaccine Adverse Event Reporting System (VAERS), 452, 636
vaccines approved since 1986, 452
- vaginal
 administration, 94
 irritation, female rabbit, 364
variant, 295
vectors, 34, 447
vehicle controls, 182, 530*t*
Virus Act of 1902 (Virus-Toxin Law; Biologics Control Act), 13, 14*t*, 30
Virus-Toxin Law *see* Virus Act of 1902
V79 lines/system *see* Chinese hamster
volume of distribution (V_D), 384*t*, 389, 561
- water solubility, 88, 93, 98, 389
Wechsler Intelligence Scale for Children (WISC), 613*t*, 620
whole-body autoradiography, 401
Wilcoxon Rank-Sum Test, 681
Wiley, Harvey, 13
Williams' t-test, 689
women of childbearing potential, 44, 298, 309, 438, 452
world marketplace for drugs, 1
World Medical Association (WMA), 598
Wright Dust-Feed (WDF), 472
- xenobiotic metabolism, minipig, 277
XPA^{-/-} mouse model, 337
zebra fish, 563